Paper22198540
Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation.
Perkins JB and 10 others. Biol Blood Marrow Transplant, 2012. Cited by 48 papers, by iCite.
Cite this record
ConductScience Library. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Papers, record 22198540. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22198540
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics22
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Busulfan | Major topic |
| Hematopoietic Stem Cell Transplantation | Major topic |
| Myeloablative Agonists | Major topic |
| Transplantation Conditioning | Major topic |
| Vidarabine | Major topic |
| Adolescent | |
| Adult | |
| Aged | |
| Area Under Curve | |
| Drug Administration Schedule | |
| Drug Dosage Calculations | |
| Female | |
| Hematologic Neoplasms | |
| Humans | |
| Male | |
| Middle Aged | |
| Prospective Studies | |
| Recurrence | |
| Survival Rate | |
| Transplantation, Homologous | |
| Treatment Outcome |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P30CA076292 | NIH |
Source NIH RePORTER
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT00361140 | Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) | Results |
Source ClinicalTrials.gov
Cited by31
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 48 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41981079 | Busulfan pharmacokinetics in adults - a real-world evaluation of intra-individual variability and the impact of obesity and deferasirox. | Bone Marrow Transplant | 2026 | https://conductscience.org/library/papers/41981079 | PubMed |
| 41557115 | Association of busulfan area under the curve with the development of neurotoxicity in children and adolescents receiving busulfan-containing conditioning regimens for stem cell transplantation. | Int J Hematol | 2026 | https://conductscience.org/library/papers/41557115 | PubMed |
| 39271948 | A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT). | Bone Marrow Transplant | 2024 | https://conductscience.org/library/papers/39271948 | PubMed |
| 38036818 | Determination of Busulfan and Melphalan in Plasma by Turbulent Flow Chromatography-Tandem Mass Spectrometry. | Methods Mol Biol | 2024 | https://conductscience.org/library/papers/38036818 | PubMed |
| 34523110 | Pharmacokinetically guided, once-daily intravenous busulfan in combination with fludarabine for elderly AML/MDS patients as a conditioning regimen for allogeneic stem cell transplantation. | Int J Hematol | 2021 | https://conductscience.org/library/papers/34523110 | PubMed |
| 34453497 | Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study. | CPT Pharmacometrics Syst Pharmacol | 2021 | https://conductscience.org/library/papers/34453497 | PubMed |
| 33512420 | The pulmonary metatranscriptome prior to pediatric HCT identifies post-HCT lung injury. | Blood | 2021 | https://conductscience.org/library/papers/33512420 | PubMed |
| 33231122 | Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS. | Leuk Lymphoma | 2021 | https://conductscience.org/library/papers/33231122 | PubMed |
| 33179758 | Predicting the presence and mechanism of busulfan drug-drug interactions in hematopoietic stem cell transplantation using pharmacokinetic interaction network-based molecular structure similarity and network pharmacology. | Eur J Clin Pharmacol | 2021 | https://conductscience.org/library/papers/33179758 | PubMed |
| 32886279 | Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine. | Int J Hematol | 2021 | https://conductscience.org/library/papers/32886279 | PubMed |
| 31834435 | Population pharmacokinetic analysis of intravenous busulfan: GSTA1 genotype is not a predictive factor of initial dose in Chinese adult patients undergoing hematopoietic stem cell transplantation. | Cancer Chemother Pharmacol | 2020 | https://conductscience.org/library/papers/31834435 | PubMed |
| 31376591 | Measurement of the DNA alkylating agents busulfan and melphalan in human plasma by mass spectrometry. | J Chromatogr B Analyt Technol Biomed Life Sci | 2019 | https://conductscience.org/library/papers/31376591 | PubMed |
| 31136799 | Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement. | Biol Blood Marrow Transplant | 2019 | https://conductscience.org/library/papers/31136799 | PubMed |
| 30108322 | Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children. | Bone Marrow Transplant | 2019 | https://conductscience.org/library/papers/30108322 | PubMed |
| 29469189 | Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation. | Br J Clin Pharmacol | 2018 | https://conductscience.org/library/papers/29469189 | PubMed |
| 29250116 | Chimerism in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and without Busulfan Pharmacokinetics versus BuCy. | Adv Hematol | 2017 | https://conductscience.org/library/papers/29250116 | PubMed |
| 29238995 | Test Dose Pharmacokinetics in Pediatric Patients Receiving Once-Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach? | J Clin Pharmacol | 2018 | https://conductscience.org/library/papers/29238995 | PubMed |
| 28766962 | Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review. | Expert Opin Drug Metab Toxicol | 2017 | https://conductscience.org/library/papers/28766962 | PubMed |
| 28733264 | The Impact of Toxicities on First-Year Outcomes after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies. | Biol Blood Marrow Transplant | 2017 | https://conductscience.org/library/papers/28733264 | PubMed |
| 28368376 | Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention. | Bone Marrow Transplant | 2017 | https://conductscience.org/library/papers/28368376 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| HLA-A | 3105 | PubTator's text mining | https://conductscience.org/library/genes/3105 | NCBI Gene |
| HLA-B | 3106 | PubTator's text mining | https://conductscience.org/library/genes/3106 | NCBI Gene |
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| FLUDARABINE | CHEMBL1568 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1568 | ChEMBL |
| BUSULFAN | CHEMBL820 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL820 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- References
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/22198540
GET https://conductscience.org/api/papers/v1/22198540/cited_by?page=2